Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial.

Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial.

Vasilevskis EE 1,

Shah AS 1,

Hollingsworth EK 1,

Shotwell MS 2,

Kripalani S 1,

Mixon AS 1,

Simmons SF 1

Author information

JAMA Internal Medicine, 01 Mar 2023, 183(3):223-231 DOI: 10.1001/jamainternmed.2022.6545 PMID: 36745422

SFhreaerefuthll itsexatrativcaleilaSbhlearaeftewri0th6 eFmebai2l0S2h4are with twitterShare with linkedinShare with facebook

ORDER A CUSTOM PAPER NOW

Abstract

Importance

Deprescribing is a promising approach to addressing the burden of polypharmacy. Few studies have initiated comprehensive deprescribing in the hospital setting among older patients requiring ongoing care in a postacute care (PAC) facility.

ORDER A CUSTOM PAPER NOW

Objective

To evaluate the efficacy of a patient-centered deprescribing intervention among hospitalized older adults transitioning or being discharged to a PAC facility.

Design, setting, and participants

This randomized clinical trial of the Shed-MEDS (Best Possible Medication History, Evaluate, Deprescribing Recommendations, and Synthesis) deprescribing intervention was conducted between March 2016 and October 2020. Patients who were admitted to an

academic medical center and discharged to 1 of 22 PAC facilities affiliated with the medical center were recruited. Patients who were 50 years or older and had 5 or more prehospital medications were enrolled and randomized 1:1 to the intervention group or control group.

Patients who were non-English speaking, were unhoused, were long-stay residents of nursing homes, or had less than 6 months of life expectancy were excluded. An intention-to- treat approach was used.

Interventions

The intervention group received the Shed-MEDS intervention, which consisted of a pharmacist- or nurse practitioner-led comprehensive medication review, patient or surrogate-approved deprescribing recommendations, and deprescribing actions that were initiated in the hospital and continued throughout the PAC facility stay. The control group received usual care at the hospital and PAC facility.

Main outcomes and measures

The primary outcome was the total medication count at hospital discharge and PAC facility discharge, with follow-up assessments during the 90-day period after PAC facility discharge. Secondary outcomes included the total number of potentially inappropriate medications at each time point, the Drug Burden Index, and adverse events.

Results

A total of 372 participants (mean [SD] age, 76.2 [10.7] years; 229 females [62%]) were randomized to the intervention or control groups. Of these participants, 284 were included in the intention-to-treat analysis (142 in the intervention group and 142 in the control group).

Overall, there was a statistically significant treatment effect, with patients in the intervention group taking a mean of 14% fewer medications at PAC facility discharge (mean ratio, 0.86; 95% CI, 0.80-0.93; P < .001) and 15% fewer medications at the 90-day follow-up (mean ratio, 0.85; 95% CI, 0.78-0.92; P < .001) compared with the control group. The intervention additionally reduced patient exposure to potentially inappropriate medications and Drug Burden Index. Adverse drug event rates were similar between the intervention and control groups (hazard ratio, 0.83; 95% CI, 0.52-1.30).

Conclusions and relevance

Results of this trial showed that the Shed-MEDS patient-centered deprescribing intervention was safe and effective in reducing the total medication burden at PAC facility discharge and 90 days after discharge. Future studies are needed to examine the effect of this intervention on patient-reported and long-term clinical outcomes

Trial registration

ClinicalTrials.gov Identifier: NCT02979353.

Full text links

 Read article at publisher’s site (DOI): 10.1001/jamainternmed.2022.6545

References

 Articles referenced by this article (43)

 

• Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG

J Biomed Inform, (2):377-381 2008

MED: 18929686

 

·          Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study.

Reeve E, Low LF, Hilmer SN

Br J Gen Pract, (649):e552-60 2016 MED: 27266865

·          Sources of medication omissions among hospitalized older adults with polypharmacy.

Shah AS, Hollingsworth EK, Shotwell MS, Mixon AS, Simmons SF, Vasilevskis EE

J Am Geriatr Soc, (4):1180-1189 2021

MED: 34967444

 

 

·          Deprescription at hospital discharge: Outcomes of a deprescription promoting campaign.

Poquet I, Tornero C

Eur J Intern Med, e22-e23 2017 MED: 28427802

·          A drug burden index to define the functional burden of medications in older people.

Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, Harris TB, Hanlon JT, Rubin SM, Shorr RI, Bauer DC, Abernethy DR

Arch Intern Med, (8):781-787 2007

MED: 17452540

 

·          The number of discharge medications predicts thirty-day hospital readmission: a cohort study.

Picker D, Heard K, Bailey TC, Martin NR, LaRossa GN, Kollef MH

BMC Health Serv Res, 282 2015

MED: 26202163

 

·          A patient-centered deprescribing intervention for hospitalized older patients with polypharmacy: rationale and design of the Shed-MEDS randomized controlled trial.

Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Mixon AS, Bell SP, Kripalani S, Schnelle JF, Simmons SF; Shed-MEDS Team, Bartoo C, Kim J, Lewallen K, Narramore W, Parker R, Lincoln S, Gupta J

BMC Health Serv Res, (1):165 2019

MED: 30871561

 

·          Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta- Analysis.

Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E

J Gerontol A Biol Sci Med Sci, (5):1020-1034 2022 MED: 34390339

 

·          The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.

Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD

Br J Clin Pharmacol, (3):583-623 2016

MED: 27077231

 

·          Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. Brunstrom M, Carlberg B

JAMA Intern Med, (1):28-36 2018

MED: 29131895

 

·          Deprescribing medicines in the acute setting to reduce the risk of falls.

Marvin V, Ward E, Poots AJ, Heard K, Rajagopalan A, Jubraj B

Eur J Hosp Pharm, (1):10-15 2016

MED: 28184303

 

·          STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria.

Gallagher P, O’Mahony D

Age Ageing, (6):673-679 2008

MED: 18829684

 

·          Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States.

Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM

JAMA Intern Med, (12):1673-1680 2018

MED: 30326004

 

·          Prevalence of Diabetes Medication Intensifications in Older Adults Discharged From US Veterans Health Administration Hospitals.

 

Anderson TS, Lee S, Jing B, Fung K, Ngo S, Silvestrini M, Steinman MA

JAMA Netw Open, (3):e201511 2020 MED: 32207832

• Impact of Deprescribing Interventions in Older Hospitalised Patients on Prescribing and Clinical Outcomes: A Systematic Review of Randomised Thillainadesan J, Gnjidic D, Green S, Hilmer SN

Drugs Aging, (4):303-319 2018

MED: 29541966

 

·          A medication review and deprescribing method for hospitalised older patients receiving multiple medications.

McKean M, Pillans P, Scott IA

Intern Med J, (1):35-42 2016

MED: 26387783

 

·          A method for estimating the probability of adverse drug reactions.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ

Clin Pharmacol Ther, (2):239-245 1981

MED: 7249508

 

·          Polypharmacy and Incident Frailty in a Longitudinal Community-Based Cohort Study.

Shmuel S, Lund JL, Alvarez C, Hsu CD, Palta P, Kucharska-Newton A, Jordan JM, Nelson AE, Golightly YM

J Am Geriatr Soc, (12):2482-2489 2019

MED: 31648378

 

·          Development of a hospital deprescribing implementation framework: A focus group study with geriatricians and pharmacists.

Scott S, Twigg MJ, Clark A, Farrow C, May H, Patel M, Taylor J, Wright DJ, Bhattacharya D

 

Age Ageing, (1):102-110 2019

MED: 31711097

 

·          Unintentional Continuation of Medications Intended for Acute Illness After Hospital Discharge: A Population-Based Cohort Study.

Scales DC, Fischer HD, Li P, Bierman AS, Fernandes O, Mamdani M, Rochon P, Urbach DR, Bell CM

J Gen Intern Med, (2):196-202 2016

MED: 26369941

 

·          Adverse events after discontinuing medications in elderly outpatients.

Graves T, Hanlon JT, Schmader KE, Landsman PB, Samsa GP, Pieper CF, Weinberger M

Arch Intern Med, (19):2205-2210 1997

MED: 9342997

 

·          Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis.

Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, Hock J, Loffler C, Kochling A, Schuler J, Flamm M, Sonnichsen A

Br J Clin Pharmacol, (2):532-548 2016

MED: 27059768

 

·          Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older: A Systematic Review and Meta-analysis.

Weiss J, Freeman M, Low A, Fu R, Kerfoot A, Paynter R, Motu’apuaka M, Kondo K, Kansagara D

Ann Intern Med, (6):419-429 2017

MED: 28114673

 

·          The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care.

 

McDonald EG, Wu PE, Rashidi B, Forster AJ, Huang A, Pilote L, Papillon-Ferland L, Bonnici A, Tamblyn R, Whitty R, Porter S, Battu K, Downar J, Lee TC

J Am Geriatr Soc, (9):1843-1850 2019

MED: 31250427

 

·          Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): cluster randomised controlled trial.

Blum MR, Sallevelt BTGM, Spinewine A, O’Mahony D, Moutzouri E, Feller

M, Baumgartner C, Roumet M, Jungo KT, Schwab N, Bretagne L, Beglinger S, Aubert CE, Wilting I, Thevelin S, Murphy K, Huibers CJA, Drenth-van Maanen AC, Boland

B, […] Rodondi N

BMJ, n1585 2021

MED: 34257088

 

·          Medications associated with geriatric syndromes and their prevalence in older hospitalized adults discharged to skilled nursing facilities.

Saraf AA, Petersen AW, Simmons SF, Schnelle JF, Bell SP, Kripalani S, Myers AP, Mixon AS, Long EA, Jacobsen JM, Vasilevskis EE

J Hosp Med, (10):694-700 2016

MED: 27255830

 

·          The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study.

Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT

J Gen Intern Med, (2):141-146 2009

MED: 19967465

 

·          MDS 3.0: brief interview for mental status.

Saliba D, Buchanan J, Edelen MO, Streim J, Ouslander J, Berlowitz D, Chodosh J

J Am Med Dir Assoc, (7):611-617 2012 MED: 22796362

 

·          A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Charlson ME, Pompei P, Ales KL, MacKenzie CR

J Chronic Dis, (5):373-383 1987

MED: 3558716

 

·          Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.

Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, Gaussoin SA, Johnson KC, King J, Kitzman DW, Kostis JB, Lerner AJ, Lewis CE, Oparil

S, Rahman M, Reboussin DM, Rocco MV, Snyder JK, Still C, […] Williamson JD

J Am Geriatr Soc, (3):496-504 2019

MED: 31840813

 

·          American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.

American Geriatrics Society 2012 Beers Criteria Update Expert Panel, Fick D, Semla T, Beizer J, Brandt N, Dombrowski R, DuBeau CE, Flanagan N, Hanlon J, Hollmann P, Linnebur S, Nau D, Rehm B, Sandhu S, Steinman M

J Am Geriatr Soc, (4):616-631 2012

MED: 22376048

 

·          Impact of deprescribing rounds on discharge prescriptions: an interventional trial.

Edey R, Edwards N, Von Sychowski J, Bains A, Spence J, Martinusen D

Int J Clin Pharm, (1):159-166 2018

MED: 30478496

 

·          Medication withdrawal trials in people aged 65 years and older: a systematic review.

Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG

Drugs Aging, (12):1021-1031 2008

MED: 19021301

 

·          Older Patient and Surrogate Attitudes Toward Deprescribing During the Transition From Acute to Post-Acute Care.

Hollingsworth EK, Shah AS, Shotwell MS, Simmons SF, Vasilevskis EE

J Appl Gerontol, (3):788-797 2022

MED: 35164584

 

·          Patient-Reported Barriers and Enablers to Deprescribing Recommendations During a Clinical Trial (Shed-MEDS).

Kim JL, Lewallen KM, Hollingsworth EK, Shah AS, Simmons SF, Vasilevskis EE

Gerontologist, (3):523-533 2023

MED: 35881109

 

·          Shed-MEDS: pilot of a patient-centered deprescribing framework reduces medications in hospitalized older adults being transferred to inpatient postacute care.

Petersen AW, Shah AS, Simmons SF, Shotwell MS, Jacobsen JML, Myers AP, Mixon AS, Bell SP, Kripalani S, Schnelle JF, Vasilevskis EE

Ther Adv Drug Saf, (9):523-533 2018

MED: 30181860

 

·          Deprescribing admission medication at a UK teaching hospital; a report on quantity and nature of activity.

Scott S, Clark A, Farrow C, May H, Patel M, Twigg MJ, Wright DJ, Bhattacharya D

Int J Clin Pharm, (5):991-996 2018

MED: 29926257

 

·          Evaluation of pharmacist-led physician-supported inpatient deprescribing model in older patients admitted to an acute general medical unit.

Potter EL, Lew TE, Sooriyakumaran M, Edwards AM, Tong E, Aung AK

Australas J Ageing, (3):206-210 2019

MED: 30868694

 

 

·          Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy.

Garfinkel D, Mangin D

Arch Intern Med, (18):1648-1654 2010

MED: 20937924

 

·          Design and analysis of nested case-control studies for recurrent events subject to a terminal event.

Jazic I, Haneuse S, French B, MacGrogan G, Rondeau V

Stat Med, (22):4348-4362 2019

MED: 31290191

 

• Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, Sawyer

JK, Weffald LA, Green AR, Reeve E, Maciejewski ML, Sheehan OC, Wolff JL, Kraus C, Boyd CM

JAMA Intern Med, (5):534-542 2022

MED: 35343999

 

·          Clinical Outcomes After Intensifying Antihypertensive Medication Regimens Among Older Adults at Hospital Discharge.

Anderson TS, Jing B, Auerbach A, Wray CM, Lee S, Boscardin WJ, Fung K, Ngo S, Silvestrini M, Steinman MA

JAMA Intern Med, (11):1528-1536 2019

MED: 31424475

 

·          Hypertension Treatment in US Long-Term Nursing Home Residents With and Without Dementia.

Boockvar KS, Song W, Lee S, Intrator O

J Am Geriatr Soc, (10):2058-2064 2019

MED: 31328791

ORDER A PLAGIARISM-FREE PAPER HERE

While you are doing that I need to still have my picot approved. I want it now on polypharmacy in a long term care facility, on how to decrease/reduce the amount of medication taken by the patients. I only want the picot question and three original articles if possible from the USA but if not one of them must come from the USA and the other two from Canada and/or the other countries approve by the school. Also it has to be prospective not rectropective, statistical analysis, and from 2018 to present with a P value of less then 0,005.

I am implementing not translating.

It is possible to get this by Friday? I know it’s short notice.

CONHCP: Doctor Of Nursing Practice Final PICOT-D Approval

The department has conducted a review of your PICOT-D question in an effort to support the development of your project. Please note that this review is a FINAL APPROVAL of the PICOT-D and will require permission by the DNP Program Lead for any changes to this statement beyond the date of this approved review. We highly discourage changes as they may prevent you from progressing.

PICOT-D Question:

Mandatory questions: Are you an APRN? What is your expected graduation year?

All projects must have a minimum of 3 original research studies to support the intervention. (One of the three original research articles to support your intervention need to come from the US or Canada). The other research studies can come from the UK, Denmark, India, New Zealand, or Australia (preferred) or from any of the 131 countries listed in the International Compilation of Human Research Standards 2020.

*** In DNP-955A You will be required to have a total of 15 research articles to support the intervention (3 from PICOT, plus other original research)Original Research Articles (Use permalinks and attach a pdf copy of each of the quantitative original research articles):

X

X

X[KF1]

IMPORTANT PLEASE STOP AND READ:

This is your Final Approved PICOT-D statement. Please maintain this copy and please include it in each course ISP going forward, in addition, this is the FINAL approved statement to be shared with all DNP course instructors going forward.

If you need to make a change to this PICOT-D statement, you must work with your current course instructor to review and approve any possible changes and your instructor must notify the DNP Program Lead. Making a change to your PICOT-D statement past this date may lead to your delay and success in this program, there must be a valid significant reason to change this PICOT-D statement going forward. It will require you to stop and re-gain permission prior to progressing. This final approval is tracked in CRM.

You may not begin your intervention or collect any data related to your project until you have GCU IRB approval, which typically occurs in 960A. Prior to your project courses, you will be working on designing a project in preparation for the submission of your proposal in 955A. Ensure you are accessing the resources in the DC network and in the classroom. You do not need to resubmit your PICOT to the department.

Congratulations on your work so far! We are so glad you have chosen Grand Canyon University.

THIS FINAL PICOT-D STATEMENT IS APPROVED.

_______________________________________________________Date: _____________________________

DNP PICOT-D REVIEWER Name/Credentials

“For it is God who works in you to will and to act in order to fulfill his good purpose.” (Philippians 2:13)

[KF1]Ensure this is in current APA format. Remove the numbers they are a reminder